Expression of programmed cell death ligand 1 (PD-L1) within tumors is an important biomarker for guiding immune checkpoint therapies; however, immunohistochemistry-based methods of detection fail to provide a comprehensive picture of PD-L1 levels in an entire patient. To facilitate quantification of PD-L1 in the whole body, we developed a peptide-based, high-affinity PD-L1 imaging agent labeled with [
Introduction
Cancer cells develop multiple mechanisms to evade immune recognition and create a microenvironment that sustains immune tolerance. 1 One of them involves interactions of immune checkpoint protein programmed cell death ligand-1 (PD-L1), expressed in tumors, with programmed cell death protein 1 (PD-1), present on immune cells, that lead to their deactivation. 2 PD-L1 is expressed in many tumor types, and its levels in the tumors assessed by immunohistochemistry may be used for patient stratification for therapy involving inhibition of PD-1/PD-L1 immune check point. 2 Two immunohistochemistry-based PD-L1 companion diagnostic tests received Food and Drug Administration approval to guide therapies targeted against PD-L1 and its receptor PD-1. 3 Those tests, however, do not fully capture the inter-and intratumoral heterogeneity in PD-L1 expression that have implications in guiding therapy. 4 Noninvasive imaging technologies, particularly positron emission tomography (PET), have the potential to quantify total PD-L1 levels in all the lesions provided that a high-affinity molecularly targeted imaging agent is available. 5 Significant efforts have been invested in developing PD-L1-targeted imaging agents. Radiolabeled antibodies, [6] [7] [8] [9] [10] [11] high-affinity ectodomains derived from PD-1, 12 and adnectinderived 13, 14 small proteins have been investigated as nuclear imaging agents. All those agents have shown promise in detecting PD-L1 expression in preclinical cancer models. Despite those developments, there is a need for radiotracers labeled with readily available positron-emitting radionuclides, such as 18 F or 68 Ga, that allow imaging of PD-L1 within 60 to 120 minutes after injection that is more adequate to clinical workflow. In a recent study, we demonstrated that a human PD-L1-specific, 14-amino acid cyclic peptide conjugated with 2,2 0 ,2 00 -(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA) and radiolabeled with 64 Cu or 68 Ga can be used to generate highcontrast images of PD-L1 expression in tumors by PET imaging and to assess the target engagement of PD-L1 therapeutics. [15] [16] [17] Because of the greater availability of 18 F and its well-suited properties for PET imaging, we pursued the development and evaluation of a radiofluorinated analog of WL12.
Here, we report the preparation of a radiofluorinated analog of WL12 using 2,3,5,6-tetrafluorophenyl 6-[ 18 
Materials and Methods

Chemicals
The PD-L1-binding peptide, WL12 (sequence shown in Figure 1A ), was custom synthesized by CPC Scientific (Sunnyvale, California) with >95% purity. 6-Fluoronicotinic acid was purchased from Combi-Blocks (San Diego, California). 18 O]H 2 O target using a General Electric PETtrace biomedical cyclotron (GE Healthcare, Chicago, Illinois). N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)pyridine-2-aminium tri-fluoromethane sulfonate was prepared as reported previously. 18 All other chemicals were purchased from Sigma-Aldrich (Milwaukee, Wisconsin) or Thermo Fisher Scientific (Waltham, Massachusetts) unless otherwise specified.
All cell culture-related reagents were purchased from Invitrogen, unless otherwise specified. Polyclonal anti-human IgG-Eu3þCryptate (catalog # 61HFCKLA) and XL665-conjugated mouse monoclonal anti-6Histidine antibody (catalog # 61HISXLA) were purchased from Cisbio Assays (Bedford, Massachusetts). Recombinant Human PD-1 Fc chimera Protein (catalog #1086-PD-050) and recombinant human PD-L1(B7-H1)-His-tag protein (catalog #9049-B7) were obtained from R&D systems (Minneapolis, Minnesota). Electrospray ionization mass spectra were obtained on a Bruker Daltronics Esquire 3000 Plus Spectrometer. Semipreparative high-performance liquid chromatography (HPLC) was performed using a system containing 2 Agilent ProStar HPLC pumps and an Agilent 1260 Infinity Diode Array detector controlled by Open Lab Software, version A.01.05 (Santa Clara, California). Radio-HPLC was performed on a Varian ProStar system (Palo Alto, California) equipped with a Varian ProStar 325 ultraviolet (UV)-visible (Vis) variable wavelength detector and a BioScan Flow-Count in-line radioactivity detector (Washington, District of Columbia), all controlled by Galaxie software (Varian, Inc. Palo Alto, California). The specific activity was calculated as the ratio of the radioactivity eluting at the retention time of the product during the semipreparative HPLC purification to the mass corresponding to the area under the UV peak. 4 mM) 6-fluoronicotinic acid dissolved in 40-mL dry tetrahydrofuran (THF) was added a solution of 2.7g (11 mM) 2,3,5,6-tetrafluorophenol dissolved in 10 mL dry THF. To this mixture was added, in small portions, a solution consisting of 2.57 g (12.4 mM) dicyclohexycarbodiimide (DCC) dissolved in 15 mL dry THF and allowed to stir at room temperature for 6 days. The reaction was filtered to remove the white biproduct, dicyclohexylurea. The filtrate was concentrated to a residue, dissolved in dichloromethane, and allowed to stand in order to precipitate more dicyclohexylurea. The procedure was repeated twice using a 10/1 solution of hexanes/ethyl acetate to remove all the dicyclohexylurea. The final filtrate was concentrated, redissolved in 30mL of 10/1 solution of hexanes/ethyl acetate, and purified on a silica gel column using the same hexane/ethyl acetate mobile phase to give 1.88g of a thick colorless oil which solidified. 
FPy-WL12. Five mg of WL12 (2.51 Â 10 À6 M) was reacted with 3.6 mg of 2,3,5,6-tetrafluorophenyl 6-fluoronicotinate (1.25 Â 10 À5 M ) in 1 mL of dimethylformamide (DMF) in the presence of 2 M equivalents of diisopropylethyl amine for 30 minutes at 60 C to provide FPy-WL12 (Supplementary Figure S1A) . The resulting peptide was purified on a Reverse phase (RP) HPLC using a 10 Â 250 mm, 5-m Luna C18 column (Phenomenex, Torrance, California) using an acetonitrile/water gradient with 0.1% trifluoroacetic acid (TFA). The elution conditions were 35% to 75% acetonitrile with 0.1%TFA at a flow rate of 5 mL/min in 25 minutes (Supplementary Figure S1B) with water þ 0.1% TFA as co-solvent. FPy-WL12 was collected at * 20 minutes of elution, and following evaporation, the resulting residue was dissolved in deionized water and lyophilized, yielding 4.5 mg of a white powder (yield 89% Fluorine-18 target water (87-100mCi) was diluted to 4 mL with high-purity water (TraceSELECT, Honeywell) and passed through a Chromafix 30-PS-HCO 3 anion exchange cartridge prewetted with 2 mL of TraceSELECT water. The cartridge was washed with 4 mL anhydrous acetonitrile and dried for 2 minutes by passing a stream of argon gas. The cartridge was then slowly eluted with a solution consisting of 5 to 11 mg of N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)-pyridine-2-aminium trifluoromethane sulfonate, dissolved in 1 mL of 4:1 t-butanol/acetonitrile. This was diluted to 2 mL with water and purified by RP-radio-HPLC (10 Â 250 mm, 10 m, Luna C18 column; Phenominex; solvent A 100% water þ0.1% TFA; solvent B 100% acetonitrile þ0.1% TFA; gradient 80% A to 20% A over 30 minutes; flow rate 4 mL/min). The desired 2,3,5,6-tetrafluorophenyl 6-[
18 F]fluoronicotinate (24-41 mCi) was collected at R t ¼ 28 minutes, diluted with water to 20 mL, loaded onto a preactivated (20mL acetonitrile followed by 20mL water) Waters C18 Sep-Pak Plus cartridge (Waters, Milford, Massachusetts), and cartridge was dried by passing argon for several minutes. A sodium sulfate drying cartridge (Grace-Davison, Columbia, Maryland) was attached to the C18 cartridge and the C18 cartridge eluted with 2 mL of methylene chloride through the drying cartridge. 18 F]fluoronicotinate was added 100 mL DMF, and this was concentrated to approximately 100 mL under a stream of argon. To this was added a solution consisting of 0.1 to 0.14 mg (50-70 nM) WL12 in 50 mL DMF and 4 mL di-isopropylethyl amine. The reaction mixture was heated at 45 C for 20 minutes, diluted with water, and purified by RP radio-HPLC (10 Â 250 mm, 10 m, Luna C18 column; solvent A 100% water þ0.1% TFA, solvent B 100% acetonitrile þ0.1% TFA; Gradient 65% A to 25% A over 25 minutes; flow 5 mL/m). The desired [
18 F]FPy-WL12 (2.8-7.8 mCi) was collected at R t ¼ 11 minutes. Unlabeled WL12 eluted at 7.5 minutes. [ 18 F]FPy-WL12 in HPLC mobile phase was evaporated under reduced pressure, reconstituted in saline containing 5% dimethylsulfoxide and 2 drops of Tween 20, and diluted with saline for in vitro and in vivo studies.
Programmed cell death ligand 1-PD-1 binding inhibition assay. Competitive PD-L1/PD-1 inhibition assay was performed as described. 15 Briefly, PD-L1-His-tag (80 nM final) in 10 mL assay buffer was preincubated for 15 minutes with varying concentrations WL12 or FPy-WL12 ranging from 1 pM to 1 mM. This was followed by addition of 5 mL of assay buffer containing PD-1-Ig (final concentration 20 nM) and incubated for 15 minutes. Then, 5 mL of assay buffer with IgG-Eu (final concentration 2 nM) and anti-6HIS-XL665 (final concentration 40 nM) was added. After 1 hour of incubation at room temperature, the plate was read on a Perkin Elmer Victor3 1420 multilabel counter (Waltham, Massachusetts). The half maximal inhibitory concentration (IC50) and Ki values were derived by fitting the data to a sigmoidal dose-response curve and the Cheng-Prusoff equation with derived K d ¼ 70 nM for PD-L1, respectively. Experiments were carried out in triplicates.
Cell Lines
Cell lines NCI-H226 (LSCC), NCI-H1155 (NSCLC), MDAMB231 (TNBC), and CHO-K1, (henceforth referred to as H226, H1155, MDAMB231, and CHO, respectively) were purchased from the American Type Culture Collection (ATCC) and passaged for fewer than 3 months after which new cultures were initiated from vials of frozen cells. The SUM149 (TNBC) cell line was kindly provided by Dr Stephen P. Ethier, Medical University of South Carolina, and authenticated by STR profiling at the Johns Hopkins genetic resources facility. SUM149 cells were maintained in Ham's F-12 medium with 5% fetal bovine serum (FBS), 1% P/S and 5 mg/mL insulin, and 0.5 mg/mL hydrocortisone. All other cell lines were cultured in ATCC-recommended media in an incubator at 37 C in an atmosphere containing 5% CO 2 . The CHO cell line stably expressing human PD-L1 (hPD-L1) was generated in our laboratory and maintained in F-12K medium with 10% FBS, 1% P/S, and 2 mg/mL G418. 
Animal Models
Animal studies were performed according to the protocols approved by the JHU Animal Care and Use Committee (ACUC). Six-to eight-week old, female, nonobese diabetic severe combined immunodeficient g (NSG) mice were obtained from the JHU Immune Compromised Animal Core (Baltimore, Mary Land). Mice were implanted subcutaneously in the upper flanks with hPD-L1 (10 Â 10 6 ), CHO (10 Â 10 6 ), ¼ 3) . The PET images were collected in 2-bed positions at 5 minutes per bed in an ARGUS small-animal PET/computed tomography (CT) scanner (Sedecal, Madrid, Spain). A CT scan (512 projections) was performed at the end of each PET scan for anatomical coregistration. Mice were anesthetized under 3% and maintained at 1.5% isofluorane during scanning. The PET data were reconstructed using the 2-dimensional ordered subsets expectation maximization algorithm (2D-OSEM) and corrected for dead time and radioactive decay. The %ID per cm 3 values were calculated based on a calibration factor obtained from a known radioactive quantity. Final data visualization and image generation were accomplished using Amira (FEI, Hillsboro, Oregon).
Ex Vivo Biodistribution
Biodistribution studies were carried out at various time points in NSG mice bearing CHO/hPD-L1 (10, 60, and 120 minutes), MDAMB231 (60 and 120 minutes), SUM 149 (120 minutes), and H226 (120 minutes) xenografts to confirm PET imaging results. Mice were injected intravenously with 740 kBq (in 200 mL) of [
18 F]FPy-WL12, sacrificed at the specified time, and blood, tumors, and selected tissues were harvested and weighed. The radioactivity in collected samples was measured in a Perkin Elmer-2480 Automatic Gamma Counter (Perkin Elmer, Waltham, Massachusetts). To demonstrate the in vivo specificity, a 50-mg blocking dose of WL12 was co-injected with [ 18 F]FPy-WL12. To calculate the percentage of injected dose per gram of tissue (%ID/g), radioactive standards in triplicate were counted with the tissues. Biodistribution data shown is mean + the standard error of the mean (SEM).
Data Analysis
Unpaired 2-tailed t test using the Prism 6 Software (GraphPad) was used for statistical analysis. P values <0.05 were considered to be significant. Figure 1A ). The specific activity achieved was 105 + 54 Ci/mM with radiochemical purity >95%.
Results
Synthesis of FPy-WL12 and [
18
F]FPy-WL12
WL12 and Fpy-WL12 Exhibit High Affinity to PD-L1
To test the binding affinity of WL12 and 19 FPy-WL12 to PD-L1, PD-1 binding to PD-L1 was assessed by Fluorescence Resonance Energy Transfer (FRET) in the presence of WL12 and 
PD-L1 Expression-Dependent In Vivo Accumulation of [ 18 F]FPy-WL12 in Different Tumor Models
We assessed the biodistribution and pharmacokinetics of [ 18 F]FPy-WL12 by PET imaging and ex vivo biodistribution studies in NSG mice bearing CHO xenografts with high and low PD-L1 expression (Figure 2 ). The PET-CT images of mice showed significantly higher accumulation of [ 18 F]FPy-WL12 in hPD-L1 tumors compared to CHO controls at 10, 30, and 60 minutes after the radiotracer injection (Figure 2A ). Confirming the in vivo specificity of [ 18 F]FPy-WL12, a significant reduction in radioactivity uptake was observed in hPD-L1 tumors in mice receiving a blocking dose of unmodified WL12. In addition to hPD-L1 tumors, high radioactivity accumulation was also observed in liver and kidneys.
We performed ex vivo biodistribution studies in mice with the same tumor models to validate the PET imaging observations. 18 F]FPy-WL12 was observed at 120 minutes. Thus, imaging and biodistribution studies in other tumor models were performed at 120 minutes to take advantage of the observed high tumor-to-muscle (and blood) and hPD-L1-to-CHO tumor ratios.
We next evaluated PD-L1 specificity of [ 18 F]FPy-WL12 in mice bearing MDAMB231 TNBC xenografts with moderate levels of endogenous PD-L1 expression. The PET-CT images of those mice indicated modest accumulation of radioactivity in MDAMB231 tumors ( Figure 3A) .
In the biodistribution studies, accumulation of [ 18 F]FPy-WL12 in MDAMB231 tumors reached 2.15 + 0.1 %ID/g at 120 minutes. Upon co-injection of [ 18 F]FPy-WL12 with WL12, radioactivity accumulation in MDAMB231 tumors was reduced to 0.81 + 0.063 %ID/g confirming radiotracer specificity ( Figure 3B ). To further validate the PD-L1 specificity, we performed biodistribution studies in mice with SUM149 tumors that have low PD-L1 expression. 8, 20 [ 18 F]FPy-WL12 accumulation was low in SUM149 tumors at 1.43 + 0.11 %ID/g (P < .001). Immunohistochemical analysis of tumors for PD-L1 expression showed high immunoreactivity in MDAMB231 tumors and low immunoreactivity in SUM149 tumors ( Figure 3C ), providing further evidence that observed radiotracer uptake is PD-L1 specific.
We also evaluated [ 18 F]FPy-WL12 uptake in the lung squamous cell carcinoma H226 xenograft model (Figure 4) . The PET-CT and ex vivo biodistribution studies showed a 2.77 + 0.31 %ID/g of radioactivity accumulation in H226 tumors at 2 hours after radiotracer injection ( Figure 4A) . A blocking dose of WL12 co-injected with the radiotracer resulted in reduced [
18 F]FPy-WL12 uptake in H226 tumors (1.28 + 0.13 %ID/g), validating the results observed in breast cancer xenografts ( Figure 4B ). The IHC analysis of tumors showed moderate immunoreactivity for PD-L1 ( Figure 4C ). Collectively, these results validated the PD-L1 specificity of [ 18 F]FPy-WL12 in tumor models with endogenous PD-L1 expression.
Discussion
Here we report the preparation and evaluation of an [
18 F]-radiolabeled PD-L1-binding peptide, [ 18 F]FPy-WL12, and demonstrated the PD-L1 specificity of the radiotracer in vitro and in vivo in several human cancer xenografts.
In a recent study, we demonstrated that a 64 Cu-labeled DOTAGA-WL12 conjugate provides high-contrast PET images of tumor PD-L1 expression in mouse models within 120 minutes. 15 Considering the rapid and specific uptake of [ 64 Cu]WL12 in PD-L1-positive tumors, we hypothesized that an 18 F-labeled WL12 analog would be more desirable for PET imaging. Fluorine-18 is well suited for clinical translation with 97% decay via positron emission and a 109.77-minute half-life that allows transportation of the radiotracer from the regional radiopharmacy to the clinical site.
With radiochemical yield (5.1 + 3.1%) is likely due to the small amount of WL12 (0.1-0.14 mg, 50-70 nM) used in the conjugation step. The average non-decay corrected (nca) yield for the first step (preparation of [
18 F]FPy-TFP) was 35% + 9% and that of conjugation step was 14% + 5%. We expect that the radiochemical yield of the conjugation step can be improved using a larger amount of WL12. Increasing WL12 would not affect specific activity of the final product when purified by preparative radio-HPLC, as there is a baseline separation between WL12 and [
18 F]FPy-WL12. Our low specific activity 3.885 + 1.998 TBq/mM (105 + 54 Ci/mM) is likely due to the low level of 18 F used for radiolabeling and the possibility of fluoride exchange occurring during the radiofluorination, where the tetrafluorophenol ester of [ 18 F]FPy-TFP is the source of the non-radioactive fluorine. We anticipate that automation, which would permit the use of higher levels of [
18 F]fluoride, would increase the specific activity of the product. Our experience with this convenient and simple synthon indicates a wide applicability of this radiolabeling strategy for preparing fluorine-18 labeled PD-L1 binding and other peptide imaging agents.
The WL12 is a first-in-class peptide-based imaging agent that enables PD-L1 detection in vivo. To take advantage of rapid pharmacokinetics often associated with peptides and to facilitate the clinical translation of WL12, we pursued radiolabeling strategies with several radionuclides. The potential of WL12 to provide high-contrast images was apparent with DOTAGA-conjugated [
64 Cu]WL12. 15 The same analog 
Conclusions
In this study, we demonstrated that WL12 can be successfully radiolabeled with [ 18 F] using an fluorine-18 labeled prosthetic group in a procedure that is amenable to automation. The resulting [
18 F]FPy-WL12 exhibited high affinity to PD-L1 and showed PD-L1 dependent in vitro cellular uptake. [ 18 F]FPy-WL12 demonstrated PD-L1 specific uptake in multiple tumors of various cancer types in PET-CT imaging and ex vivo biodistribution studies. However, it is possible that WL12 when radiolabeled with F-18 using Al 18 F chelation methods may produce the improved pharmacokinetics similar to those previously reported for 68 Ga-and 64 Cu-labeled WL12 due to decreased lipophilicity and off-target uptake.
Author Contribution
Wojciech G. Lesniak and Ronnie C. Mease contributed equally.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
